Feb 17, 2009|
An unflattering inheritance
Double whammy for the new government
Just as Barack Obama became President of the United States of America at a time when the US was in the midst of its worst crisis ever, so will the new Indian government inherit finances which are in an absolutely sorry state. As reported by the acting Finance Minister Pranab Mukherjee in his interim budget speech yesterday, India's fiscal deficit will stand at an appalling 6% of GDP in FY09. That he expects the same to reduce to 5.5% of GDP in FY10 is hardly a matter of comfort. Certainly, the new government will have a tough task on its hands getting this percentage down especially in a scenario when the global financial crisis has not abated.
The fiscal deficit can be curbed either by raising tax revenues or curbing expenditures. The problem for the government is that it has its hands more or less tied on both fronts. Not surprisingly, as a fallout of the slowdown, tax receipts have been waning. At the same time, if the economy has to revive, the government will have to spend to boost demand. Subsidies continue to be a major spoke in the wheel and the government did nothing really to address the issue when the Indian economy was growing at a scorching pace.
These subsidies on food, fertilizers and petroleum among others make up the third largest component of the government's non-plan expenditure after interest costs and defence spending. In fact, efforts to curb spending were done by compromising on capital expenditure which does not bode well given the poor state of India's infrastructure. Indeed, the new government will seriously need to get its act together to address the issue of the soaring fiscal deficit, which if uncontrolled could harm India's economic health.
Glaxo's largesse to poorest countries
As seeking a larger share of the pie and improving profitability gets increasingly difficult in developed nations, some of the largest pharma companies are willing to compromise margins to get an entry into unchartered territories. As per Wall Street Journal, GlaxoSmithKline (GSK) Plc, the second-largest pharmaceutical company in the world has signaled a groundbreaking change by promising to cap the prices of the patented medicines that it sells in the poorest countries.
In fact, the company's management has indicated that it would not even hesitate from sharing critical knowledge about potential generic drugs that are currently protected by patents. GSK Plc has decided to significantly reduce the price of the drugs that it sells in 50 sub-Saharan African countries. It plans to charge not more than 25% of the average price that it charges for the same drugs in the developed world, as long as it can cover costs. GSK currently garners revenues of about £30 m annually from selling drugs to the 50 countries and has operations in 14 of them.
The quandary of ethanol producers
The ethanol industry which was in limelight last year on account of higher crude prices is now in a serious jeopardy. With the US economy slowing down and demand for cars falling, the ethanol industry is burdened with excess capacity. To add fuel to the fire, while oil prices have plunged, the prices of corn from which nearly all commercial ethanol in the US is made has continued to remain high. No wonder then that excess capacity is posing a problem. As per Renewable Fuels Association, out of 180 plants in the US, nearly 25 plants have been closed over the last three months. Recently, in order to reduce dependence on foreign oil, US had mandated doubling of corn ethanol use. However, with the deepening recession, meeting the target would most likely be difficult.
In India, while the government is taking steps to encourage the ethanol sector, the scenario here is not bright either. There is a shortage of sugarcane of up to 30%, due to which the availability of molasses will be on lower side. This in turn will translate into higher raw material costs. Also, with the auto industry in doldrums, lower demand for cars would only mean lower offtake.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
Aug 18, 2017
Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407